Topotecan in platinum-resistant epithelial ovarian cancer.
BACKGROUND
Topotecan has been emerged as a new promising anticancer drug for patients with ovarian cancer.


METHODS
In this study, patients who were treated with topotecan were reviewed retrospectively. A total of 26 patients was included the study. All patients had received platinum-based regimens previously. Topotecan was administered a dose of 1.5 mg/m(2) intravenously 30 min daily for 5 days and repeated every 21 days.


RESULTS
The response rates were 30% by CA-125 level and 29% in clinic evaluation. Median duration of response was 8 (3-15) months, median progression-free interval was 12 (4-30) months and median overall survival was 15 (4-36) months. Grade 3-4 neutropenia occurred in 58% of the patients (38% of the courses) and trombocytopenia in 29% of the patients (12% of the courses). Nonhematological toxicities were mild. There was no drug-related death.


CONCLUSIONS
Topotecan is considered as a reasonable option for treatment of patients with platinum refractory recurrent ovarian cancer.
Karabulut
Bulent
B
Division of Medical Oncology, Ege University School of Medicine, Bornova/Izmir, Turkey.
Sezgin
Canfeza
C
Terek
Mustafa Cosan
MC
Uslu
Ruchan
R
Sanli
Ulus A
UA
Akman
Levent
L
Ozsaran
Aydin
A
Dikmen
Yilmaz
Y
Goker
Erdem
E
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D008875:Middle Aged; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy* / Q000401:mortality; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality; D017671:Platinum Compounds / Q000494:pharmacology; D012189:Retrospective Studies; D015996:Survival Rate; D019772:Topotecan / Q000009:adverse effects / Q000627:therapeutic use*; D014421:Turkey / Q000453:epidemiology
D000970:Antineoplastic Agents; D017671:Platinum Compounds; D019772:Topotecan